Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
作者信息
Tolaney Sara M, Ziehr David R, Guo Hao, Ng Mei R, Barry William T, Higgins Michaela J, Isakoff Steven J, Brock Jane E, Ivanova Elena V, Paweletz Cloud P, Demeo Michelle K, Ramaiya Nikhil H, Overmoyer Beth A, Jain Rakesh K, Winer Eric P, Duda Dan G
出版信息
Oncologist. 2021 Aug;26(8):e1483. doi: 10.1002/onco.13809. Epub 2021 May 12.
Abstract
摘要
相似文献
1
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.卡博替尼用于转移性三阴性乳腺癌患者的II期及生物标志物研究。
Oncologist. 2021 Aug;26(8):e1483. doi: 10.1002/onco.13809. Epub 2021 May 12.
2
Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with Cabozantinib.
Clin Imaging. 2018 Mar-Apr;48:44-47. doi: 10.1016/j.clinimag.2017.09.014. Epub 2017 Sep 28.
3
A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.卡博替尼单药或联合曲妥珠单抗治疗乳腺癌脑转移患者的 II 期研究。
Breast Cancer Res Treat. 2020 Jan;179(1):113-123. doi: 10.1007/s10549-019-05445-z. Epub 2019 Sep 20.
4
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.卡博替尼用于转移性乳腺癌：一项II期安慰剂对照随机停药研究的结果
Breast Cancer Res Treat. 2016 Nov;160(2):305-312. doi: 10.1007/s10549-016-4001-y. Epub 2016 Oct 6.
5
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
6
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.替凡替尼（ARQ 197）用于转移性三阴性乳腺癌患者的II期研究。
Invest New Drugs. 2015 Oct;33(5):1108-14. doi: 10.1007/s10637-015-0269-8. Epub 2015 Jul 1.
7
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.卡博替尼治疗转移性去势抵抗性前列腺癌后血浆生物标志物的变化：一项II期试验扩展队列的事后分析
J Transl Med. 2016 Jan 13;14:12. doi: 10.1186/s12967-015-0747-y.
8
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.帕博利珠单抗对比研究者选择化疗用于转移性三阴性乳腺癌（KEYNOTE-119）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4.
9
Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.卡博替尼：一种MET、RET和VEGFR2酪氨酸激酶抑制剂。
Recent Results Cancer Res. 2014;201:207-14. doi: 10.1007/978-3-642-54490-3_12.
10
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.卡博替尼用于晚期实体瘤患者的II期随机停药试验。
Eur J Cancer. 2017 Nov;86:296-304. doi: 10.1016/j.ejca.2017.09.011. Epub 2017 Oct 20.
引用本文的文献
1
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.PEARL：一项在人表皮生长因子受体2阴性乳腺癌新辅助化疗前将放射治疗添加到帕博利珠单抗中的Ib/II期生物标志物研究。
J Clin Oncol. 2024 Dec 20;42(36):4282-4293. doi: 10.1200/JCO.24.00003. Epub 2024 Sep 19.
2
Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis.三阴性乳腺癌研究中的全球生物标志物趋势：一项文献计量分析
Int J Surg. 2024 Dec 1;110(12):7962-7983. doi: 10.1097/JS9.0000000000001799.
3
Modulation of cabozantinib efficacy by the prostate tumor microenvironment.前列腺肿瘤微环境对卡博替尼疗效的调节作用。
Oncotarget. 2017 Sep 23;8(50):87891-87902. doi: 10.18632/oncotarget.21248. eCollection 2017 Oct 20.
Zotero 插件